Alvotech’s creditors have expressed confidence in the fledgling business and strengthened its balance sheet, electing to convert a portion of debt into equity “at an exercise price that gives the company a pre-money valuation of $2.7bn.”
Through a private bond offering at the very end of 2018, the Icelandic biosimilars specialist raised $300m to further develop its biosimilar assets, “fuel continued growth” and to refinance existing debt
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?